Indication: Oral Mucositis
A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy
Pts receiving chemo for Head & Neck cancer
Sub-indication: Therapy trial to reduce severe oral mucositis
Line of Therapy: Newly diagnosed
Principal Investigator: Aaron Spalding, M.D.Norton Cancer Institute
Sponsor: Oragenics Inc.
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org